Tagged Articles

type 2 diabetes drugs 15 articles

Research hints at new therapies for pancreatic cancer patients

Researchers have found a way to coax pancreatic cancer cells to revert back to normal cells by adding a protein that binds to specific DNA sequences and controls the genes involved in the growth and differentiation of the cells. The finding offers a glimmer of hope to people with pancreatic cancer, a disease that claims about 40,000 lives a year. “For the first time, we have shown that overexpression of a single gene can reduce the tumor-promoting potential of pancreatic adenocarcinoma cells and reprogram them toward their original cell type. Thus, pancreatic cancer cells retain a genetic memory which we ... Read More

Cough medicine may help lower blood sugar in diabetic patients

An ingredient found in over-the-counter cough medicines may help lower blood sugar levels and could one day be used for the treatment of type 2 diabetes, according to new research published in the journal Nature Medicine. Researchers at Heinrich Heine University in Dusseldorf, Germany, have discovered that the drug dextromethorphan, when consumed, metabolizes into a compound called dextrorphan. This compound is what triggers the insulin release from the pancreas. The drug suppresses the activity of certain receptors called N-Methyl-D-Aspartate (NMDA) in the medulla oblongata, located in the brainstem just above the spinal cord. NMDA receptors also are found in the ... Read More

Trials underway on experimental diabetes drug

Novo Nordisk’s new oral diabetes drug is proving to be just as effective as its injectable counterpart in clinical studies. The drug, known as OG217SC, is an oral version of the company’s experimental weekly injectable medication semaglutide, from a class of type 2 diabetes drugs known as glucagon-like peptide-1 receptor agonist, or GLP-1 drugs. The drugs work by promoting the body’s natural production of insulin, which not only helps manage insulin levels but also can with weight loss. Weight gain is a contributing factor in type 2 diabetes and many diabetic patients are encouraged to lose weight by following a ... Read More

Scientists developing breakthrough therapies for pancreatic cancer

Breakthrough therapies are currently in development designed to improve survival in patients with pancreatic cancer, one of the deadliest forms of the disease, the Food and Drug Administration (FDA) announced. Patients with pancreatic cancer often don’t experience symptoms of the disease until it has spread to other parts of the body, when it is more difficult to treat. The most common symptoms that bring patients to the doctor are jaundice, back pain and unexplained weight loss. Other symptoms include new onset diabetes or worsening diabetes, nausea, vomiting, bowel changes, tiredness, weakness, and changes in appetite. Surgery is the only hope ... Read More

Long-standing diabetics with pancreatic cancer have worse prognosis than non-diabetics

Diabetic patients with pancreatic cancer have a worse survival rate than non-diabetics with pancreatic cancer, according to an analysis published in the Journal of Clinical Oncology. Pancreatic cancer is one of the deadliest forms of the disease, with most patients surviving less than a year after diagnosis. Diabetics are also more likely to develop pancreatic cancer than non-diabetics. The cancer risk is greater in patients who have had type 2 diabetes for several years. The study involved 1,006 patients from the Nurses’ Health Study and the Health Professionals Follow-Up Study, all of whom had been diagnosed with pancreatic cancer between 1986 ... Read More

Januvia, Byetta associated with more deaths, hospitalizations than other diabetes drugs

The type 2 diabetes drugs Januvia (sitagliptin phosphate) and Byetta (exenatide) have been associated with 1,844 deaths and 11,540 hospitalizations, according to a MedPage Today and Milwaukee Wisconsin Journal Sentinel analysis of health care provider and pharmaceutical company adverse event reports. “Under the FDA’s system, drug companies are required to file (drug-related adverse event) reports – but patients and doctors often don’t report incidents to the drug makers. In addition to health care providers, patients can report the incidents directly to the FDA. The database may include duplicates – though the last time the federal Government Accountability Office did a ... Read More

Type 2 diabetes can be prevented, reversed by following healthy lifestyle

Type 2 diabetes can be prevented or even reversed with simple lifestyle changes, according to Dr. Eberhard Standl, a diabetes expert and spokesman for the European Society of Cardiology (ESC). Type 2 diabetes has grown in epidemic proportions, with 400 million diabetics and another 400 million pre-diabetics around the world. The chronic disease contributes to serious health concerns including heart disease, kidney disease, dementia, amputations due to neuropathy, some forms of cancer, and blindness. The disease contributed to an estimated 5 million deaths in 2014 alone. Once known as adult-onset diabetes, type 2 diabetes now affects as many as 80,000 ... Read More

Top best-selling Type 2 diabetes drugs linked to cancer

Nearly half of the top-selling Type 2 diabetes drugs come from a class of drugs known as incretin mimetics. They have been linked to a painful inflammation of the pancreas called acute pancreatitis, and an increased risk of pancreatic cancer. The list, compiled by Genetic Engineering & Biotechnology News, ranks FDA-approved type 2 diabetes drugs based on sales for the year 2013. Drugs not included in the list include those whose sales figures were withheld, such as Johnson & Johnson’s Invokana (canagliflozin), as well as the several treatments approved during 2014, such as Boehringer Ingelheim’s Jardiance (empagliflozin), Eli Lilly’s Trulicity (dulaglutuide) ... Read More

Plaintiffs want information on cases of pancreatic cancer associated with type 2 diabetes drugs

A federal judge denied plaintiffs’ motion to gather drug companies’ analysis of pancreatic cancer cases among users of their type 2 diabetes drugs; however, his decision is still pending regarding plaintiffs’ request to gather adverse event reports involving those drugs submitted to the U.S. Food and Drug Administration (FDA). U.S. District Judge Anthony Battaglia is presiding over a multidistrict litigation (MDL) involving about 460 plaintiffs who allege they developed pancreatic cancer after taking one of four drugs in a class of type 2 diabetes drugs known as incretin mimetics. The lawsuits name Amylin Pharmaceuticals and Eli Lilly & Co., for the drug Byetta; Merck ... Read More

Pancreatic cancer research grows as cases of the disease increase

Several organizations and philanthropies are banding together to find more effective treatments for pancreatic cancer, one of the most deadly forms of the disease. Entertainment industry’s Stand Up to Cancer (SU2C) initiative, family philanthropies, the advocacy group Pancreatic Cancer Action Network (PanCan), and the PanCan-inspired federal “recalcitrant cancer” law are making it possible for medical centers to test chemotherapies, targeted therapies, immunotherapies and other treatments for pancreatic cancer patients. Pancreatic cancer has a 6 percent five-year survival rate and is the fourth leading cause of cancer related-deaths. However, cases of the disease are growing, and experts say the disease will ... Read More